Search research articles
Contact Us
Filters
Showing results (401-410 of 480) with videos related to
Page
of 48
Sort By:
Cambridge Prisms. Precision Medicine
|
May 3, 2024
Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm
Nesrine Lajmi, Sofia Alves-Vasconcelos, Apostolos Tsiachristas, et al.
Pilot and Feasibility Studies
|
December 15, 2016
The iBRA (implant breast reconstruction evaluation) study: protocol for a prospective multi-centre cohort study to inform the feasibility, design and conduct of a pragmatic randomised clinical trial comparing new techniques of implant-based breast reconstruction
Shelley Potter, Elizabeth J Conroy, Paula R Williamson, et al.
Leukemia
|
November 27, 2019
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
Ilaria S Pagani, Phuong Dang, Verity A Saunders, et al.
The Journal of Molecular Diagnostics : JMD
|
May 13, 2022
RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid Leukemia
Naranie Shanmuganathan, Carol Wadham, Daniel Thomson, et al.
International Journal of Hematology
|
May 19, 2009
A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL
Arinobu Tojo, Kensuke Usuki, Akio Urabe, et al.
NAR Genomics and Bioinformatics
|
April 14, 2025
TRanscriptome ANalysis of StratifiEd CohorTs (TRANSECT) enables automated assessment of global gene regulation linked to disparate expression in user defined genes and gene sets
John Toubia, Yasir Kusay, Muneeza Maqsood, et al.
Blood
|
May 27, 2014
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
Susan Branford, David T Yeung, Wendy T Parker, et al.
Leukemia
|
September 2, 2017
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
T P Hughes, B Leber, F Cervantes, et al.
Leukemia
|
June 19, 2019
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia
Susan Branford, Dennis Dong Hwan Kim, Jane F Apperley, et al.
Blood
|
September 2, 2025
Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations
Naranie Shanmuganathan, David T Yeung, Carol Wadham, et al.
Page
of 48
Search research articles
Search
Showing results (401-410 of 480) with videos related to
Sort By:
Page
of 48
Cambridge Prisms. Precision Medicine
|
May 3, 2024
Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm
Nesrine Lajmi, Sofia Alves-Vasconcelos, Apostolos Tsiachristas, et al.
Pilot and Feasibility Studies
|
December 15, 2016
The iBRA (implant breast reconstruction evaluation) study: protocol for a prospective multi-centre cohort study to inform the feasibility, design and conduct of a pragmatic randomised clinical trial comparing new techniques of implant-based breast reconstruction
Shelley Potter, Elizabeth J Conroy, Paula R Williamson, et al.
Leukemia
|
November 27, 2019
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
Ilaria S Pagani, Phuong Dang, Verity A Saunders, et al.
The Journal of Molecular Diagnostics : JMD
|
May 13, 2022
RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid Leukemia
Naranie Shanmuganathan, Carol Wadham, Daniel Thomson, et al.
International Journal of Hematology
|
May 19, 2009
A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL
Arinobu Tojo, Kensuke Usuki, Akio Urabe, et al.
NAR Genomics and Bioinformatics
|
April 14, 2025
TRanscriptome ANalysis of StratifiEd CohorTs (TRANSECT) enables automated assessment of global gene regulation linked to disparate expression in user defined genes and gene sets
John Toubia, Yasir Kusay, Muneeza Maqsood, et al.
Blood
|
May 27, 2014
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
Susan Branford, David T Yeung, Wendy T Parker, et al.
Leukemia
|
September 2, 2017
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
T P Hughes, B Leber, F Cervantes, et al.
Leukemia
|
June 19, 2019
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia
Susan Branford, Dennis Dong Hwan Kim, Jane F Apperley, et al.
Blood
|
September 2, 2025
Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations
Naranie Shanmuganathan, David T Yeung, Carol Wadham, et al.
Page
of 48